• 3625 Citations
  • 20 h-Index
20002019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Bilal Piperdi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Safety Medicine & Life Sciences
Adenocarcinoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications 2000 2019

  • 3625 Citations
  • 20 h-Index
  • 47 Article
  • 1 Chapter
  • 1 Comment/debate
  • 1 Editorial
6 Citations (Scopus)

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

Leighl, N. B., Hellmann, M. D., Hui, R., Carcereny, E., Felip, E., Ahn, M. J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., Patnaik, A., Gubens, M., Ramalingam, S. S., Lubiniecki, G. M., Zhang, J., Piperdi, B. & Garon, E. B., Apr 1 2019, In : The Lancet Respiratory Medicine. 7, 4, p. 347-357 11 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Therapeutics
Survival
Random Allocation
Ligands
1 Citation (Scopus)

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

Levy, B. P., Giaccone, G., Besse, B., Felip, E., Garassino, M. C., Domine Gomez, M., Garrido, P., Piperdi, B., Ponce-Aix, S., Menezes, D., MacBeth, K. J., Risueño, A., Slepetis, R., Wu, X., Fandi, A. & Paz-Ares, L., Feb 1 2019, In : European Journal of Cancer. 108, p. 120-128 9 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Placebos
Disease-Free Survival
pembrolizumab
Confidence Intervals

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study

Dietel, M., Savelov, N., Salanova, R., Micke, P., Bigras, G., Hida, T., Antunez, J., Guldhammer Skov, B., Hutarew, G., Sua, L. F., Akita, H., Chan, O. S. H., Piperdi, B., Burke, T., Khambata-Ford, S. & Deitz, A. C., Aug 1 2019, In : Lung Cancer. 134, p. 174-179 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Multicenter Studies
Ligands
Neoplasms
Mutation

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

Nosaki, K., Saka, H., Hosomi, Y., Baas, P., de Castro, G., Reck, M., Wu, Y. L., Brahmer, J. R., Felip, E., Sawada, T., Noguchi, K., Han, S. R., Piperdi, B., Kush, D. A. & Lopes, G., Sep 1 2019, In : Lung Cancer. 135, p. 188-195 8 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Safety
Ligands
Neoplasms
Drug Therapy
4 Citations (Scopus)

Development of a method to implement whole-genome bisulfite sequencing of cfDNA from cancer patients and a mouse tumor model

Maggi, E. C., Gravina, S., Cheng, H., Piperdi, B., Yuan, Z., Dong, X., Libutti, S. K., Vijg, J. & Montagna, C., Jan 23 2018, In : Frontiers in Genetics. 9, JAN, 6.

Research output: Contribution to journalArticle

DNA Methylation
Genome
DNA
Neoplasms
Neuroendocrine Tumors